What's in Lihir Medical Centre's pipeline?

Lihir Medical Centre has 8 drugs in our index: 3 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Lihir Medical Centre's portfolio?

Top competitors by shared drug class: London School of Hygiene and Tropical Medicine, University of Oxford, Ain Shams Maternity Hospital, Baqiyatallah Medical Sciences University, Celltrion.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lihir-medical-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Lihir Medical Centre — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lihir Medical Centre pipeline: 3 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
R2-Total targeted treatment with azithromycin	R2-Total targeted treatment with azithromycin	marketed
R3-Total targeted treatment with azithromycin	R3-Total targeted treatment with azithromycin	marketed
R3-Total community treatment with azithromycin	R3-Total community treatment with azithromycin	marketed
Diethylcarbamazine on day 1	Diethylcarbamazine on day 1	phase 3	Microfilaricide	Microfilarial neuromuscular system	Parasitic Infection / Tropical Medicine
Azithromycin on Day 1	Azithromycin on Day 1	phase 3	Macrolide antibiotic	Bacterial 50S ribosomal subunit	Infectious Disease
Albendazole on Day 1	Albendazole on Day 1	phase 3	Benzimidazole anthelmintic	β-tubulin	Infectious Disease / Parasitology
Ivermectin on Day 1	Ivermectin on Day 1	phase 3	Macrocyclic lactone antiparasitic	Glutamate-gated chloride channels (GluCl)	Infectious Disease / Parasitology
Azithromycin on Day 8	Azithromycin on Day 8	phase 3	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)	Infectious Disease

Therapeutic area mix

Infectious Disease · 2
Infectious Disease / Parasitology · 2
Parasitic Infection / Tropical Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

London School of Hygiene and Tropical Medicine · 2 shared drug classes
University of Oxford · 2 shared drug classes
Ain Shams Maternity Hospital · 1 shared drug class
Baqiyatallah Medical Sciences University · 1 shared drug class
Celltrion · 1 shared drug class
Copenhagen Studies on Asthma in Childhood · 1 shared drug class
Grünenthal GmbH · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lihir Medical Centre:

Cite this brief

Drug Landscape (2026). Lihir Medical Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lihir-medical-centre. Accessed 2026-05-16.